Compare iShares Core S&P 500 ETF (IVV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core S&P 500 ETF vs Merck & Co., Inc. — how do they compare? iShares Core S&P 500 ETF trades at $748.93, while Merck & Co., Inc. trades at $124.78 (market cap $307.25B). The key difference: Merck & Co., Inc. pays a 2.73% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals.
| IVV | MRK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $763.10 | $129.52 |
52-Week Low | $624.65 | $77.60 |
Market Cap | — | $307.25B |
Enterprise Value | — | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVV, tracking the S&P 500, trades at $745.67, down 0.14% with a bearish technical signal from moving averages. The fund remains heavily weighted toward technology stocks, with recent news highlighting concentration risks and debates over valuation. A dividend of $2.00 is scheduled for June 2026, providing income amid market volatility.
Outlook is cautious due to technical weakness and high tech exposure, though long-term growth prospects from AI and earnings strength offer potential. Key risks include market concentration, valuation concerns, and macroeconomic shifts impacting broad index performance.
Merck (MRK) trades at $127.5, down slightly (-0.14%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $137.30. The company reported strong earnings beats in recent quarters, with Q1 2026 loss narrower than expected, and maintains robust profitability with a net income margin of 13.59%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
The outlook for MRK is positive, supported by earnings momentum, strategic acquisitions, and strong analyst buy ratings (67.57%). Key risks include rising debt levels, with debt-to-asset ratio increasing to 36.06% in 2025, and competitive pressures in the pharmaceutical sector. The stock offers a dividend yield with a recent $0.85 per share payment, appealing for income-focused investors amid steady revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
